FLUTICASONE SUMMARY
Fluticasone Propionate Lotion, 0.05% contains fluticasone propionate [S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate, 17-propionate], a synthetic fluorinated corticosteroid, for topical dermatologic use. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.
Fluticasone Propionate Lotion is indicated for the relief of the inflammatory and
pruritic manifestations of atopic dermatitis in patients 1 year of age or older.
The safety and efficacy of drug use for longer than 4 weeks in this population have not been established.
The safety and efficacy of Fluticasone Propionate Lotion in pediatric patients below 1 year of age have not been established.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Fluticasone (Fluticasone Topical)
Efficacy, dose reduction, and resistance to high-dose fluticasone in patients
with eosinophilic esophagitis. [2014] esophagitis (EoE) and analyzed esophageal transcriptomes to identify mechanisms... CONCLUSIONS: Daily administration of a high dose of FP induces histologic
Fluticasone impact on airway dendritic cells in smokers: a randomized controlled
trial. [2013] DCs in smokers are unknown... CONCLUSIONS: Resistance to ICS monotherapy in smokers might in part be due to
An integrated analysis of the efficacy of fluticasone furoate nasal spray versus
placebo on the nasal symptoms of perennial allergic rhinitis. [2013] Intranasal corticosteroids are widely prescribed for the treatment of perennial
allergic rhinitis (PAR). The aim of this analysis was to determine whether the
beneficial effects of once-daily (q.d.) fluticasone furoate nasal spray (FFNS)
effectively improved individual nasal symptoms of PAR...
MP29-02 (a novel intranasal formulation of azelastine hydrochloride and
fluticasone propionate) in the treatment of seasonal allergic rhinitis: a
randomized, double-blind, placebo-controlled trial of efficacy and safety. [2012] Many patients with allergic rhinitis (AR) have uncontrolled symptoms despite
available treatment options. This study was designed to evaluate the efficacy and
safety of MP29-02 (a novel intranasal formulation of fluticasone propionate [FP]
and azelastine [AZ] hydrochloride), compared with monotherapy with FP, AZ, and
placebo sprays for the treatment of seasonal allergic rhinitis (SAR)...
Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. [2011.10.06] ABSTRACT: BACKGROUND: Fluticasone furoate (FF) is a novel long-acting inhaled corticosteroid (ICS). This double-blind, placebo-controlled randomized study evaluated the efficacy and safety of FF 200 mcg or 400 mcg once daily, either in the morning or in the evening, and FF 200 mcg twice daily (morning and evening), for 8 weeks in patients with persistent asthma... CONCLUSIONS: FF at total daily doses of 200 mcg or 400 mcg was significantly more effective than placebo. FF 400 mcg once daily in the evening had similar efficacy to FF 200 mcg twice daily and all FF regimens had a safety tolerability profile generally similar to placebo. This indicates that inhaled FF is an effective and well tolerated once-daily treatment for mild-to-moderate asthma. TRIAL REGISTRATION: NCT00398645.
Clinical Trials Related to Fluticasone (Fluticasone Topical)
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With Asthma [Completed]
This purpose of this study is to show the superiority and long term safety and efficacy of
adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid
(fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of
asthma control will provide key information on the efficacy and safety of the combination
therapy. The safety measure will be an assessment of adverse events
Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution [Recruiting]
When a drug company first develops a drug, the company has to show the Food and Drug
Administration (FDA) that the drug is safe and effective. If FDA concludes that the drug is
safe and effective, FDA approves the drug. The company can then sell the drug, which the
company does using "trade name." Only the drug company that developed the "trade name" drug
is allowed to sell it. However, other drug companies can create their own version of the
"trade name" drug, which usually happens after the patents for the "trade name" product run
out. These drugs, often called "generic drugs," potentially will be less expensive for the
patient. In order to sell generic drugs, drug companies must show that their generic
version is the same as the "trade name" drug in a number of ways. For example, they
generally have to show that their product is intended to be used to treat the same diseases
or conditions, that it has the same label, and that the product has the same active
ingredient as the "trade name" drug. The generic company also has to show that generic
product is "bioequivalent" to the trade name drug, meaning that the generic product gets to
the part of the body where the drug works at the same rate that the trade name drug does.
How to show how much drug gets to the part of the body where it works, and how fast, depends
on the type of product the drug is. The primary aim of this research study is to aid the
FDA in finding methods to ensure that the versions of generic drugs that are inhaled (for
example, drugs used to treat asthma) are bioequivalent to the trade name drug. As a part of
the research study, pharmacokinetic (PK) studies (studies measuring drug levels in the blood
over time after inhalation) will be done using three different versions of fluticasone
propionate (FP, a drug routinely used in asthmatic patients) administered using a dry powder
inhaler (DPI, an inhalation device that delivers the drug as a dry powder). The results
from this study will help FDA ensure that generic products are the same as the trade name
drugs.
A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 [Completed]
To demonstrate the non-inferiority of QVA149 110/50 µg o. d. to fluticasone/salmeterol 500/50
µg b. i.d. in terms of trough Forced Expiratory Volume in one second (FEV1) (mean of 23 hours
15 min and 23 hours 45 min post QVA149 dose) following 26 weeks of treatment in patients
with moderate to severe COPD
Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler [Completed]
The purpose of this study is to demonstrate dose proportionality of fluticasone furoate (FF)
and equivalence of vilanterol (VI)following single dose administration of FF/VI via the
novel dry powder inhaler in healthy subjects.
Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays [Completed]
The primary objective is to assess the effect of azelastine hydrochloride (AZE) on the
relative bioavailability (AUC0-∞) of fluticasone propionate (FLU) when administered as fixed
AZE-FLU combination product (TEST) compared to a similar formulation without containing AZE
(i. e. FLU alone in the MP29-02 vehicle; REF).
The secondary objectives are to compare the relative bioavailability (AUC0-∞) of FLU when
administered either as fixed AZE-FLU combination product (TEST) or as marketed FLU product,
Fluticasone Propionate Nasal Spray, Roxane Laboratories (COMP); To compare the effects of
AZE on other pharmacokinetic parameters of FLU (AUC0 tlast, CL/f, Cmax, tmax, t½); To assess
adverse events.
Reports of Suspected Fluticasone (Fluticasone Topical) Side Effects
Mental Status Changes (3),
Hypokalaemia (3),
Polymedication (3),
Cushing's Syndrome (3),
Dysarthria (3),
Hypertension (3),
Oedema Peripheral (2),
Condition Aggravated (2),
Toxicity TO Various Agents (2),
Toxic Neuropathy (2), more >>
|
|
Page last updated: 2014-11-30
|